IHH Healthcare Berhad | Annual Report 2024 42 Strategic Report Operations Review Performance Indicators Financial FY2023 FY2024 Revenue RM1.3 billion RM1.5 billion EBITDA RM0.07 billion RM0.1 billion Greater China Our network in Greater China consists of healthcare facilities in Hong Kong and Shanghai. In Hong Kong, we operate Gleneagles Hong Kong, a multi-specialty tertiary hospital, as well as clinics and ambulatory care centres. In Shanghai, our network comprises the newly opened Parkway Shanghai Hospital, clinics and an ambulatory care centre which will be added in 2025. When fully ramped up, Parkway Shanghai Hospital will offer a comprehensive range of medical specialties and healthcare services. Key Growth Areas • Extending healthcare continuum in Hong Kong. • Expanding bed capacity in Hong Kong • Ramping up operations and expanding clinical offerings in both Hong Kong and Shanghai Performance Highlights Gleneagles Hospital Hong Kong (GHK) • Introduced a treatment protocol combining surgery with brachytherapy in head and neck cancer treatment, a significant advancement in cancer care and medical excellence. • Launched the Gleneagles Clinical Trials Centre, co-managed by GHK and The University of Hong Kong (HKU) Clinical Trials Centre, and marking an important milestone in serving patients better. • Opened its third clinic, Gleneagles Healthcare Novum Place as part of GHK’s strategy to expand services across the healthcare continuum. • Was the first hospital in Asia to implement uniBOT, a robotic medication cutting and repacking system, enhancing patient safety and operations efficiency. • Hosted the Greater Bay Area (GBA) International Oncology Symposium 2024 with The University of Hong Kong-Shenzhen Hospital and the HKU Li Ka Shing Faculty of Medicine. The event featured over 30 cancer experts who spoke about the latest advances in oncological care. Parkway Shanghai • Continued build-up of IHH’s healthcare ecosystem in Shanghai, with strengthened operations within the hospital and a new ambulatory care centre to be opened in 2025. Outlook With a rapidly ageing population and the need to meet age-related illnesses, Hong Kong’s healthcare expenditure is among the highest in Asia. In response, IHH will continue to expand its services across the healthcare continuum, in line with local healthcare agendas. Our multidisciplinary clinics and ambulatory care centres have allowed us to reach communities in different locations, making high-quality healthcare more accessible to all. In Shanghai, we are turning around underperforming assets through rebranding our clinics and improving insurance penetration. In addition, we are keeping up with efforts to attract more healthcare professionals to join the private healthcare sector.
RkJQdWJsaXNoZXIy NDgzMzc=